

Grant S Stewart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8707516/publications.pdf>

Version: 2024-02-01

164
papers

7,001
citations

93792

39
h-index

84171

75
g-index

174
all docs

174
docs citations

174
times ranked

12965
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	670
2	Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. <i>Science</i> , 2018, 361, 594-599.	6.0	511
3	Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. <i>Cell</i> , 2018, 173, 611-623.e17.	13.5	398
4	Spatiotemporal immune zonation of the human kidney. <i>Science</i> , 2019, 365, 1461-1466.	6.0	281
5	Clinical Utility of an Epigenetic Assay to Detect Occult Prostate Cancer in Histopathologically Negative Biopsies: Results of the MATLOC Study. <i>Journal of Urology</i> , 2013, 189, 1110-1116.	0.2	200
6	Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. <i>BJU International</i> , 2012, 110, 614-628.	1.3	197
7	Epidemiology and screening for renal cancer. <i>World Journal of Urology</i> , 2018, 36, 1341-1353.	1.2	183
8	Prognostic factors and prognostic models for renal cell carcinoma: a literature review. <i>World Journal of Urology</i> , 2018, 36, 1943-1952.	1.2	162
9	PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. <i>Nature Communications</i> , 2018, 9, 746.	5.8	156
10	Pathophysiology of cancer cachexia: Much more than host-tumour interaction?. <i>Clinical Nutrition</i> , 2007, 26, 667-676.	2.3	153
11	BOD1L Is Required to Suppress Deleterious Resection of Stressed Replication Forks. <i>Molecular Cell</i> , 2015, 59, 462-477.	4.5	146
12	ctDNA monitoring using patient-specific sequencing and integration of variant reads. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	116
13	Oncometabolites in renal cancer. <i>Nature Reviews Nephrology</i> , 2020, 16, 156-172.	4.1	113
14	Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. <i>BJU International</i> , 2012, 110, 1608-1617.	1.3	111
15	Radiomics of computed tomography and magnetic resonance imaging in renal cell carcinoma—a systematic review and meta-analysis. <i>European Radiology</i> , 2020, 30, 3558-3566.	2.3	106
16	Identification of the First ATRIP-Deficient Patient and Novel Mutations in ATR Define a Clinical Spectrum for ATRIP Seckel Syndrome. <i>PLoS Genetics</i> , 2012, 8, e1002945.	1.5	104
17	A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. <i>BJU International</i> , 2005, 95, 791-793.	1.3	101
18	Embryonal precursors of Wilms tumor. <i>Science</i> , 2019, 366, 1247-1251.	6.0	101

#	ARTICLE	IF	CITATIONS
19	Cancer cachexia and fatigue. <i>Clinical Medicine</i> , 2006, 6, 140-143.	0.8	96
20	The relevance of a hypoxic tumour microenvironment in prostate cancer. <i>BJU International</i> , 2010, 105, 8-13.	1.3	94
21	Mutations in DONSON disrupt replication fork stability and cause microcephalic dwarfism. <i>Nature Genetics</i> , 2017, 49, 537-549.	9.4	81
22	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. <i>European Urology</i> , 2019, 76, 754-764.	0.9	80
23	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4064-4075.	0.8	78
24	Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. <i>Prostate</i> , 2016, 76, 1078-1087.	1.2	74
25	TRAIIP promotes DNA damage response during genome replication and is mutated in primordial dwarfism. <i>Nature Genetics</i> , 2016, 48, 36-43.	9.4	74
26	Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. <i>Oncology Reports</i> , 2008, 20, 1561-7.	1.2	74
27	Mutations in the NHEJ Component XRCC4 Cause Primordial Dwarfism. <i>American Journal of Human Genetics</i> , 2015, 96, 412-424.	2.6	71
28	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. <i>European Urology Focus</i> , 2019, 5, 857-866.	1.6	67
29	What can molecular pathology contribute to the management of renal cell carcinoma?. <i>Nature Reviews Urology</i> , 2011, 8, 255-265.	1.9	66
30	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. <i>Genome Medicine</i> , 2020, 12, 23.	3.6	66
31	Endoscopic Versus Laparoscopic Management of Noninvasive Upper Tract Urothelial Carcinoma: 20-Year Single Center Experience. <i>Journal of Urology</i> , 2013, 189, 2054-2061.	0.2	65
32	The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6924-6934.	3.2	62
33	Elasticity as a biomarker for prostate cancer: a systematic review. <i>BJU International</i> , 2014, 113, 523-534.	1.3	62
34	A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma. <i>Nature Communications</i> , 2019, 10, 1152.	5.8	60
35	Preclinical Evaluation of the Versius Surgical System, a New Robot-assisted Surgical Device for Use in Minimal Access Renal and Prostate Surgery. <i>European Urology Focus</i> , 2021, 7, 444-452.	1.6	58
36	Quantitative diagnostics of soft tissue through viscoelastic characterization using time-based instrumented palpation. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2015, 41, 149-160.	1.5	56

#	ARTICLE	IF	CITATIONS
37	Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. <i>BMJ Open</i> , 2020, 10, e035938.	0.8	54
38	Is There a Human Homologue to the Murine Proteolysis-Inducing Factor?. <i>Clinical Cancer Research</i> , 2007, 13, 4984-4992.	3.2	47
39	Long-Term Comparative Outcomes of Open Versus Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial-Cell Carcinoma After a Median Follow-Up of 13 Years. <i>Journal of Endourology</i> , 2011, 25, 1329-1335.	1.1	43
40	NF- κ B-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis. <i>Cancer Discovery</i> , 2018, 8, 850-865.	7.7	41
41	Current evidence on screening for renal cancer. <i>Nature Reviews Urology</i> , 2020, 17, 637-642.	1.9	41
42	NO α sulindac inhibits the hypoxia response of PCa prostate cancer cells via the Akt signalling pathway. <i>International Journal of Cancer</i> , 2009, 124, 223-232.	2.3	39
43	Surgical service centralisation in Australia versus choice and quality of life for rural patients. <i>Medical Journal of Australia</i> , 2006, 185, 162-163.	0.8	38
44	Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2014, 66, 956-963.	0.9	38
45	DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions. <i>Biochemical Pharmacology</i> , 2011, 81, 203-210.	2.0	37
46	Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4013-4022.	1.8	35
47	Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4212-4223.	3.2	33
48	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery—Results from RECUR Consortium. <i>European Urology Oncology</i> , 2021, 4, 473-482.	2.6	33
49	Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 22-41.	2.6	33
50	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , 2021, 108, 106482.	0.8	33
51	A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003489.	3.9	33
52	Dermcidin expression confers a survival advantage in prostate cancer cells subjected to oxidative stress or hypoxia. <i>Prostate</i> , 2007, 67, 1308-1317.	1.2	32
53	Genomics and clinical correlates of renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1899-1911.	1.2	32
54	The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. <i>BMC Medicine</i> , 2019, 17, 182.	2.3	30

#	ARTICLE	IF	CITATIONS
55	Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). <i>European Urology</i> , 2019, 75, 261-264.	0.9	30
56	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e92-e99.	0.9	30
57	Differential Expression of Prognostic Proteomic Markers in Primary Tumour, Venous Tumour Thrombus and Metastatic Renal Cell Cancer Tissue and Correlation with Patient Outcome. <i>PLoS ONE</i> , 2013, 8, e60483.	1.1	30
58	A Critical Analysis of the Learning Curve and Postlearning Curve Outcomes of Two Experience- and Volume-Matched Surgeons for Laparoscopic and Robot-Assisted Radical Prostatectomy. <i>Journal of Endourology</i> , 2015, 29, 939-947.	1.1	27
59	A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 9.	1.1	27
60	Bi-allelic Variants in TONSL Cause SPONASTRIME Dysplasia and a Spectrum of Skeletal Dysplasia Phenotypes. <i>American Journal of Human Genetics</i> , 2019, 104, 422-438.	2.6	27
61	Single cell derived mRNA signals across human kidney tumors. <i>Nature Communications</i> , 2021, 12, 3896.	5.8	27
62	DONSON and FANCM associate with different replisomes distinguished by replication timing and chromatin domain. <i>Nature Communications</i> , 2020, 11, 3951.	5.8	26
63	Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. <i>European Urology Oncology</i> , 2020, 3, 168-173.	2.6	25
64	What are the Oncological Risks of Minimal Access Surgery for the Treatment of Urinary Tract Cancer?. <i>European Urology</i> , 2004, 46, 415-420.	0.9	24
65	Contemporary practice and technique-related outcomes for radical prostatectomy in the UK: a report of national outcomes. <i>BJU International</i> , 2015, 115, 753-763.	1.3	24
66	Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. <i>World Journal of Urology</i> , 2018, 36, 417-425.	1.2	24
67	The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer. <i>Nature</i> , 2022, 606, 999-1006.	13.7	24
68	Targeted SERS nanosensors measure physicochemical gradients and free energy changes in live 3D tumor spheroids. <i>Nanoscale</i> , 2016, 8, 16710-16718.	2.8	23
69	Quality of life outcomes in patients with localised renal cancer: a literature review. <i>World Journal of Urology</i> , 2018, 36, 1961-1972.	1.2	23
70	Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement. <i>European Urology Focus</i> , 2020, 6, 991-998.	1.6	23
71	The Use of Automated Quantitative Analysis to Evaluate Epithelial-to-Mesenchymal Transition Associated Proteins in Clear Cell Renal Cell Carcinoma. <i>PLoS ONE</i> , 2012, 7, e31557.	1.1	22
72	The operative safety and oncological outcomes of laparoscopic nephrectomy for T3 renal cell cancer. <i>BJU International</i> , 2012, 110, 884-890.	1.3	22

#	ARTICLE	IF	CITATIONS
73	Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 167.e17-167.e23.	0.8	22
74	Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. <i>European Urology</i> , 2017, 71, 845-847.	0.9	22
75	Risk Prediction Models for Kidney Cancer: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 1380-1390.	1.6	22
76	The dermcidin gene in cancer: role in cachexia, carcinogenesis and tumour cell survival. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2008, 11, 208-213.	1.3	21
77	The continuing medical education activities and attitudes of Australian doctors working in different clinical specialties and practice locations. <i>Australian Health Review</i> , 2009, 33, 47.	0.5	21
78	Reduction of pro-tumorigenic activity of human prostate cancer-associated fibroblasts using Dlk1 or SCUBE1. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 530-6.	1.2	20
79	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group Study. <i>European Journal of Cancer</i> , 2017, 80, 55-62.	1.3	18
80	Hyperpolarized ¹³ C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma—A Proof of Principle Study. <i>Cancers</i> , 2022, 14, 335.	1.7	18
81	Current Status of Focal Cryoablation for Small Renal Masses. <i>Urology</i> , 2016, 90, 9-15.	0.5	17
82	Consultation audio-recording reduces long-term decision regret after prostate cancer treatment: A non-randomised comparative cohort study. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2016, 14, 308-314.	0.8	17
83	A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). <i>British Journal of Cancer</i> , 2022, 127, 1051-1060.	2.9	17
84	Description and Validation of a Modular Training System for Laparoscopic Nephrectomy. <i>Journal of Endourology</i> , 2012, 26, 1512-1517.	1.1	16
85	Hypomorphic Mutations in TONSL Cause SPONASTRIME Dysplasia. <i>American Journal of Human Genetics</i> , 2019, 104, 439-453.	2.6	16
86	A Simple Clinical Tool for Stratifying Risk of Clinically Significant CKD after Nephrectomy: Development and Multinational Validation. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1107-1117.	3.0	16
87	Functional and oncological outcomes of men under 60 years of age having endoscopic surgery for prostate cancer are optimal following intrafascial endoscopic extraperitoneal radical prostatectomy. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2011, 9, 65-71.	0.8	15
88	Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. <i>Cancers</i> , 2016, 8, 77.	1.7	15
89	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). <i>Scandinavian Journal of Urology</i> , 2019, 53, 14-20.	0.6	15
90	Acceptability and potential impact on uptake of using different risk stratification approaches to determine eligibility for screening: A population-based survey. <i>Health Expectations</i> , 2021, 24, 341-351.	1.1	15

#	ARTICLE	IF	CITATIONS
91	Mass spectrometric detection of candidate protein biomarkers of cancer cachexia in human urine. <i>International Journal of Oncology</i> , 2010, 36, 973-82.	1.4	14
92	Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials. <i>Nature Reviews Urology</i> , 2017, 14, 753-759.	1.9	14
93	Dynamic epigenetic changes to <i>VHL</i> occur with sunitinib in metastatic clear cell renal cancer. <i>Oncotarget</i> , 2016, 7, 25241-25250.	0.8	14
94	The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2022, 22, 99.	1.1	14
95	Five-year oncological outcomes of endoscopic extraperitoneal radical prostatectomy (EERPE) for prostate cancer: results from a medium-volume UK centre. <i>BJU International</i> , 2014, 113, 449-457.	1.3	12
96	Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?. <i>European Urology Focus</i> , 2018, 4, 972-977.	1.6	12
97	Setting Research Priorities in Partnership with Patients to Provide Patient-centred Urological Cancer Care. <i>European Urology</i> , 2019, 75, 891-893.	0.9	12
98	UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time. <i>Urology</i> , 2020, 136, 162-168.	0.5	12
99	A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound. <i>European Urology Focus</i> , 2021, 7, 407-419.	1.6	12
100	Identifying opportunities for timely diagnosis of bladder and renal cancer via abnormal blood tests: a longitudinal linked data study. <i>British Journal of General Practice</i> , 2022, 72, e19-e25.	0.7	12
101	Risk models for recurrence and survival after kidney cancer: a systematic review. <i>BJU International</i> , 2022, 130, 562-579.	1.3	12
102	A Novel Bovine Model for Training Urological Surgeons in Laparoscopic Radical Nephrectomy. <i>Journal of Endourology</i> , 2011, 25, 1377-1383.	1.1	11
103	Renal cell carcinoma: standards and controversies. <i>World Journal of Urology</i> , 2018, 36, 1889-1890.	1.2	11
104	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. <i>BMJ Open</i> , 2020, 10, e044566.	0.8	11
105	The influence of hypoxia on the prostate cancer proteome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 980-993.	1.4	11
106	Early detection of kidney cancer using urinary proteins: a truly non-invasive strategy. <i>BJU International</i> , 2022, 129, 290-303.	1.3	11
107	A community jury study exploring the public acceptability of using risk stratification to determine eligibility for cancer screening. <i>Health Expectations</i> , 2022, 25, 1789-1806.	1.1	11
108	Matched-Pair Analysis of Open versus Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Cell Carcinoma. <i>Urologia Internationalis</i> , 2015, 94, 156-162.	0.6	10

#	ARTICLE	IF	CITATIONS
109	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1973-1980.	1.2	10
110	Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 1141-1151.	1.5	10
111	Tissue Quality Assessment Using a Novel Direct Elasticity Assessment Device (The E-Finger): A Cadaveric Study of Prostatectomy Dissection. <i>PLoS ONE</i> , 2014, 9, e112872.	1.1	9
112	Public attitudes towards screening for kidney cancer: an online survey. <i>BMC Urology</i> , 2020, 20, 170.	0.6	9
113	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1772-1782.	0.8	9
114	The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers. <i>Journal of Visualized Experiments</i> , 2013, , .	0.2	8
115	Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. <i>BMC Medicine</i> , 2017, 15, 118.	2.3	8
116	Three-Dimensional Printed Molds for Image-Guided Surgical Biopsies: An Open Source Computational Platform. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 736-748.	1.0	8
117	The Management of Acute Urinary Retention: Treating the Curse of the Aging Male. <i>Current Bladder Dysfunction Reports</i> , 2013, 8, 242-249.	0.2	7
118	Quantitative mechanical assessment of the whole prostate gland ex vivo using dynamic instrumented palpation. <i>Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine</i> , 2017, 231, 1081-1100.	1.0	7
119	The Anorexia-Cachexia Syndrome. , 2009, , 587-595.		7
120	Proteolysis-inducing factor core peptide mediates dermcidin-induced proliferation of hepatic cells through multiple signalling networks. <i>International Journal of Oncology</i> , 2011, 39, 709-18.	1.4	6
121	Utilizing mRNA extracted from small, archival formalin-fixed paraffin-embedded prostate samples for translational research: assessment of the effect of increasing sample age and storage temperature. <i>International Urology and Nephrology</i> , 2011, 43, 961-967.	0.6	6
122	A Generation of Laparoscopic Nephrectomy: Stage-Specific Surgical and Oncologic Outcomes for Laparoscopic Nephrectomy in a Single Center. <i>Journal of Endourology</i> , 2013, 27, 1008-1014.	1.1	6
123	Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 438.e11-438.e21.	0.8	6
124	The current state of genetic risk models for the development of kidney cancer: a review and validation. <i>BJU International</i> , 2022, 130, 550-561.	1.3	6
125	Patient specific modeling of palpation-based prostate cancer diagnosis: effects of pelvic cavity anatomy and intrabladder pressure. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2016, 32, e02734.	1.0	5
126	Immunotherapy for Renal Cancer: Sequencing and Combinations. <i>European Urology Focus</i> , 2016, 2, 582-588.	1.6	5

#	ARTICLE	IF	CITATIONS
127	A novel method for rapid and quantitative mechanical assessment of soft tissue for diagnostic purposes: A computational study. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2018, 34, e2917.	1.0	5
128	Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 3377-3383.	1.2	5
129	Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?. <i>BJU International</i> , 2021, 128, 386-394.	1.3	5
130	Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib. <i>BJU International</i> , 2022, 130, 244-253.	1.3	5
131	The burden of performing minimal access surgery: ergonomics survey results from 462 surgeons across Germany, the UK and the USA. <i>Journal of Robotic Surgery</i> , 2022, 16, 1347-1354.	1.0	5
132	The Molecular Biology of Renal Cancer: Another Piece of the Puzzle. <i>European Urology</i> , 2014, 66, 85-86.	0.9	4
133	Reasons for intending to accept or decline kidney cancer screening: thematic analysis of free text from an online survey. <i>BMJ Open</i> , 2021, 11, e044961.	0.8	4
134	Validation and public health modelling of risk prediction models for kidney cancer using the UK Biobank. <i>BJU International</i> , 2022, 129, 498-511.	1.3	4
135	Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma. <i>PLoS ONE</i> , 2021, 16, e0258988.	1.1	4
136	The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol. <i>BMC Cancer</i> , 2021, 21, 1238.	1.1	4
137	Adult Prepuceplasty: Comparison of Outcomes of Standard Prepuceplasty and Foreskin Z-plasty. <i>Urology</i> , 2012, 80, 946-950.e1.	0.5	3
138	Translational research will fail without surgical leadership: SCOTRRCC a successful surgeon-led Nationwide translational research infrastructure in renal cancer. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2015, 13, 181-186.	0.8	3
139	Striated Muscle in Radical Prostatectomy Specimens: A Marker of Apical Dissection Quality and an Independent Predictor of Urinary Continence after Endoscopic Extraperitoneal Radical Prostatectomy. <i>Urologia Internationalis</i> , 2017, 98, 71-78.	0.6	3
140	The COVID Stones Collaborative: How has the Management of Ureteric Stones Changed During and After the COVID-19 Pandemic? Rationale and Study Protocol. <i>Journal of Endoluminal Endourology</i> , 2020, 3, e22-e28.	0.2	3
141	Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. <i>Programme Grants for Applied Research</i> , 2018, 6, 1-528.	0.4	3
142	Risk prediction models for symptomatic patients with bladder and kidney cancer: a systematic review. <i>British Journal of General Practice</i> , 2022, 72, e11-e18.	0.7	3
143	Predicting cancer outcomes after resection of high-risk RCC. <i>Nature Reviews Urology</i> , 2022, 19, 257-258.	1.9	3
144	Controversial Cases in Endourology. <i>Journal of Endourology</i> , 2006, 20, 612-615.	1.1	2

#	ARTICLE	IF	CITATIONS
145	Multidisciplinary urological engagement in translational renal cancer research. <i>BJU International</i> , 2014, 114, 474-475.	1.3	2
146	Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 293-297.	2.1	2
147	Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights. <i>Journal of Clinical Oncology</i> , 2017, 35, 3895-3897.	0.8	2
148	Expert Elicitation to Inform a Cost-Effectiveness Analysis of Screening for Renal Cancer. <i>Value in Health</i> , 2019, 22, 981-987.	0.1	2
149	Disagreement in risk groups for metastatic renal cancer. <i>Nature Reviews Urology</i> , 2019, 16, 332-333.	1.9	2
150	The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro. <i>Biology</i> , 2020, 9, 74.	1.3	2
151	Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 3823-3831.	1.2	2
152	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. <i>Contemporary Clinical Trials</i> , 2021, 108, 106481.	0.8	2
153	Computerized Image Analysis of Tumor Cell Nuclear Morphology Can Improve Patient Selection for Clinical Trials in Localized Clear Cell Renal Cell Carcinoma. <i>Journal of Pathology Informatics</i> , 2020, 11, 35.	0.8	2
154	Real world outcomes of biopsy-proven oncocytic neoplasm of the kidney managed by surveillance. <i>BJUJ Compass</i> , 0, , .	0.7	2
155	Re: Clinical Validation of a Targeted Methylation-based Multi-cancer Early Detection Test Using an Independent Validation Set. <i>European Urology</i> , 2022, 82, 442-443.	0.9	2
156	RESULTS OF A DEFINITIVE STUDY ARE NEEDED TO PROVIDE GUIDANCE ON THE TREATMENT OF PATIENTS WITH SCREEN-DETECTED, 'LOW-GRADE' PROSTATE CANCER. <i>BJU International</i> , 2006, 98, 944-945.	1.3	1
157	The Development of Prognostic and Predictive Biomarkers in Renal Cell Cancer Are Not One and the Same Thing. <i>European Urology</i> , 2015, 67, 21-22.	0.9	1
158	Management of a Renal Mass in a Solitary Kidney: To Freeze or To Cut?. <i>European Urology</i> , 2018, 73, 260-261.	0.9	1
159	Improving patient-clinician communication following nephrectomy in renal cell carcinoma: Development, content validation and pilot testing of a conversation aid tool. <i>Patient Education and Counseling</i> , 2021, 104, 99-108.	1.0	1
160	Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials. <i>British Journal of Cancer</i> , 2022, 126, 204-210.	2.9	1
161	Re: Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response. <i>European Urology</i> , 2008, 53, 1085.	0.9	0
162	Partial nephrectomy versus thermal ablation for clinical T1 renal tumours. <i>Annals of Translational Medicine</i> , 2019, 7, S363-S363.	0.7	0

#	ARTICLE	IF	CITATIONS
163	Immunohistochemistry as a tool for screening rare renal cancers. <i>Annals of Translational Medicine</i> , 2019, 7, S314-S314.	0.7	0
164	Re: Transcriptomic Signatures Related to the Obesity Paradox in Patients with Clear Cell Renal Cell Carcinoma: A Cohort Study. <i>European Urology</i> , 2020, 77, 656-657.	0.9	0